Skip to Content

MK-1293 Approval Status

MK-1293 is an investigational follow-on biologic insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes.

Development Status and FDA Approval Process for MK-1293

DateArticle
Aug  5, 2016Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide